Dr. Eben Rosenthal from Stanford University School of Medicine discussed clinical studies evaluating the use of fluorescently labeled anti-EGFR antibodies in the detection of primary tumor and lymph nodes in head and neck cancer. This evidence concerns the gene EGFR and head and neck cancer.